All In Biotech

Drug Trial Radar · NCT00264303

CUTE (Chronic Urticaria Treatment Evaluation)

A Comparative Study on Clinical Efficacy and Safety of Levocetirizine 5 mg Oral Capsules Once Daily in the Morning vs. Desloratadine 5 mg Oral Capsules Once Daily in the Morning in Patients Suffering From Chronic Idiopathic Urticaria (CIU)

Last checked: Nov 20, 2026Latest source record: Aug 31, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 886 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

886

Actual

Start

Dec 2005

Primary completion

Jan 2007

Study completion Jan 2007

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Dec 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus severity score over the first week of treatment

Conditions

  • Chronic Idiopathic Urticaria

Interventions

  • LevocetirizineDrug

    5mg oral capsules, once daily, 4 week duration

  • DesloratadineDrug

    5mg oral capsules, once daily, 4 week duration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Pruritus Severity Score Over the First Week of TreatmentTime frame: over the first week of treatment

Locations

80 sites in 9 countries. Site status is shown where the registry gives one.

  • Site not named

    Bruges, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Merksem, Belgium

  • Site not named

    Sint-Niklaas, Belgium

  • Site not named

    Woluwe-St-Lamb, Belgium

  • Site not named

    Bernay, France

  • Site not named

    Besançon, France

  • Site not named

    Hyères, France

  • Site not named

    Les Milles, France

  • Site not named

    Marseille, France

  • Site not named

    Montpellier, France

  • Site not named

    Nancy, France

  • Site not named

    Nantes, France

  • Site not named

    Nice, France

  • Site not named

    Nîmes, France

  • Site not named

    Paris, France

  • Site not named

    Poitiers, France

  • Site not named

    Quimper, France

  • Site not named

    Saint-Mandé, France

  • Site not named

    Troyes, France

  • Site not named

    Valence, France

  • Site not named

    Villejuif, France

  • Site not named

    Augsburg, Germany

  • Site not named

    Berlin, Germany

  • Site not named

    Cologne, Germany

  • Site not named

    Dresden, Germany

  • Site not named

    Düsseldorf, Germany

  • Site not named

    Erlangen, Germany

  • Site not named

    Göttingen, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Hanover, Germany

  • Site not named

    Leipzig, Germany

  • Site not named

    Mahlow, Germany

  • Site not named

    Mainz, Germany

  • Site not named

    München, Germany

  • Site not named

    Viersen, Germany

  • Site not named

    Caserta, Italy

  • Site not named

    Catania, Italy

  • Site not named

    Cesena, Italy

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.